774 studies found for:    parkinson's a2a
Show Display Options
Rank Status Study
1 Completed A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease
Condition: Parkinson's Disease
Intervention: Genetic: AAV-hAADC-2
2 Recruiting AADC Gene Therapy for Parkinson's Disease
Condition: Parkinson's Disease
Intervention: Genetic: AAV2-hAADC
3 Terminated A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (P05664 AM5)
Condition: Parkinson Disease
Interventions: Drug: Preladenant 2 mg tablet;   Drug: Preladenant 5 mg tablet;   Drug: Preladenant 10 mg tablet;   Drug: Rasagiline 1 mg capsule;   Drug: Placebo for Rasagiline 1 mg capsule;   Drug: Placebo for Preladenant
4 Recruiting Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Drug: Pramipexole / Rasagiline Mesylate once daily;   Drug: Placebo
5 Recruiting AAV2-GDNF for Advanced Parkinson s Disease
Condition: Parkinson's Disease
Intervention: Genetic: Convection enhanced delivery/AAV2-GDNF
6 Recruiting Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease
Condition: Parkinson's Disease
Intervention: Drug: GM608
7 Completed Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease
Condition: Idiopathic Parkinson's Disease
Interventions: Drug: Transdermal nicotine;   Other: Usual drug treatment of Parkinson's disease
8 Unknown  Clinical, Molecular and by Neuroimaging of LRRK2 Mutations
Condition: Parkinson's Disease
Intervention:
9 Completed Optimization of fMRI for the Study of Basal Ganglia Activation in Parkinson's Disease
Condition: Parkinson's Disease
Intervention: Device: MAGNETOM Avanto (MRI device)
10 Completed
Has Results
A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients
Condition: Early Parkinson's Disease
Interventions: Drug: SPM 962;   Drug: placebo
11 Completed
Has Results
Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
Condition: Parkinson's Disease
Interventions: Drug: 2 mg perampanel;   Drug: 4 mg perampanel;   Drug: placebo comparator
12 Active, not recruiting A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.
Condition: Parkinson Disease
Interventions: Drug: Ropinirole CR 2mg tablet;   Drug: Ropinirole CR 8mg tablet;   Drug: Ropinirole CR matching Placebo tablet
13 Terminated
Has Results
Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease
Condition: Advanced Idiopathic Parkinson's Disease
Interventions: Other: Placebo;   Other: Rotigotine
14 Completed A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
Condition: Parkinson's Disease
Interventions: Drug: Istradefylline;   Drug: Placebo
15 Terminated Characteristics of Parkinson s Disease Associated With the LRRK-2 Gene Mutation
Condition: Parkinson Disease
Intervention:
16 Recruiting LRRK2 Mutation and Parkinson's Disease
Condition: Parkinson Disease
Interventions: Genetic: Healthy;   Genetic: PKD Patients
17 Recruiting A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Drug: Rotigotine (Test product PR 2.3.1);   Drug: Rotigotine (Reference product PR 2.1.1)
18 Recruiting LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease
Condition: Parkinson's Disease
Intervention:
19 Recruiting Study of the Enteric Nervous System Using Colonic Biopsies in Parkinson Patients With LRRK2 Mutation
Condition: Parkinson's Disease
Intervention: Other: colonoscopy or rectosigmoidoscopy
20 Recruiting Post-prandial Hypotension and Sleepiness in Parkinson's Disease and Other Synucleinopathies
Conditions: Parkinsonian Patients;   Post-prandial Sleepiness;   Orthostatic Hypotension
Interventions: Other: V1: HGPO + meal and V2: placebo + meal;   Other: V1: placebo 75mg + meal and V2: HGPO 75mg + meal

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years